Biote Corp. filings document the public-company disclosures of a Nasdaq-listed hormone optimization and healthy aging business. Recent Form 8-K reports furnish quarterly and annual operating results, including procedure revenue, dietary supplement revenue, margins, adjusted EBITDA measures and commercial-priorities commentary for the Biote-certified provider network.
The company’s SEC record also includes Regulation FD investor presentation filings, definitive proxy materials for annual meeting matters, and securities information for its Class A common stock. Other material-event filings address operational and financial effects of a voluntary recall involving specific hormone pellet lots shipped by Asteria Health, Biote’s wholly owned 503B manufacturer of compounded bioidentical hormones.
biote Corp. (BTMD) received an amended Schedule 13G/A from investor Amit Mohan Agarwal reporting his beneficial ownership of the company’s Class A securities.
He reports beneficially owning 2,400,000 shares, representing 8.37% of the class, with sole power to vote and dispose of all 2,400,000 shares and no shared voting or dispositive power.
biote Corp. (BTMD) has a significant shareholder reported on Schedule 13G/A. Private investor Amit Agarwal disclosed beneficial ownership of 2,182,860 Class A shares of biote Corp., representing 7.61% of the class. He reports sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive power.
biote Corp. (BTMD) has a new large shareholder disclosure. Amit Agarwal, a U.S. private investor, reports beneficial ownership of 1,700,000 Class A shares of biote Corp., representing 5.92% of the class. He reports sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive power.
biote Corp. director and Executive Chairman Marc D. Beer reported two open-market purchases of Class A Common Stock. On August 10, 2026, he purchased 115,950 shares at a weighted average price of $1.53 per share in transactions ranging from $1.46–$1.55. On August 11, 2026, he purchased an additional 16,000 shares at a weighted average price of $1.55 per share, with trade prices between $1.53–$1.60. All reported holdings are direct, and these transactions total 131,950 shares of net buying.
biote Corp. reported weaker results for the three months ended June 30, 2026. Total revenue was $44,232 thousand, down from $48,863 thousand a year earlier, as pellet procedure revenue declined while dietary supplement revenue grew modestly. Selling, general and administrative expense rose to $32,426 thousand from $24,223 thousand, including $5,100 thousand of charges tied to legal settlements and other resolved matters. Income from operations swung to a loss of $3,508 thousand compared with income of $10,765 thousand in 2025. Net loss attributable to stockholders was $6,563 thousand versus net income of $3,185 thousand, or basic and diluted loss per share of $0.23.
For the six months ended June 30, 2026, revenue was $89,167 thousand versus $97,855 thousand and net loss attributable to stockholders was $4,286 thousand versus net income of $16,903 thousand. Cash and cash equivalents declined to $11,168 thousand from $24,123 thousand at December 31, 2025, as net cash provided by operating activities fell to $2,726 thousand and the company used cash for share repurchases and settlement of a prior share repurchase liability. In May 2026, biote entered an amended and restated credit agreement providing a $125,000 thousand term loan and $50,000 thousand revolving facility maturing in 2031; term loan principal outstanding was $125,000 thousand at June 30, 2026. Total liabilities were $159,891 thousand and stockholders’ deficit was $58,192 thousand. All amounts are in thousands.
Biote Corp. reported second quarter 2026 revenue of $44.2 million, down 9.5% from $48.9 million a year earlier. Procedure revenue declined 13.9% to $30.3 million, reflecting impacts from the January 2026 voluntary recall of certain hormone pellets shipped by Asteria Health, while dietary supplements revenue grew 5.7% to $11.4 million.
Gross profit margin fell to 65.4% from 71.6%, driving an operating loss of $3.5 million versus $10.8 million of income, and a net loss of $7.4 million, or $(0.23) per diluted share, compared with $3.9 million and $0.10. Adjusted EBITDA was $5.6 million with a 12.6% margin, down from $15.2 million and 31.1%. Recall-related costs totaled $0.8 million in the quarter and $2.2 million year-to-date. As of June 30, 2026, cash was $11.2 million, total liabilities were $159.9 million, and stockholders’ deficit was $58.2 million. For 2026, Biote now guides to revenue above $175 million and Adjusted EBITDA above $25 million, expecting sequential improvement but continued year-over-year declines in procedure revenue, with dietary supplements growing at a mid to high single-digit rate.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of Class A stock of BIOTE CORP. BlackRock reports beneficial ownership of 359,732 shares, representing 1.2% of the outstanding Class A shares. All of these shares are reported with sole voting and sole dispositive power, with no shared voting or dispositive power. The filing states that various underlying persons may have rights to dividends or sale proceeds, but no such person holds more than five percent of the total outstanding common shares.
biote Corp. amended and restated the employment agreement for Robert Peterson in connection with his role as Interim Chief Executive Officer. Under the new terms, he will receive an annual base salary of $658,800 plus eligibility for an annual incentive of up to 72.5% of base salary.
Peterson will be granted stock options to purchase a number of shares equal to 0.56% of biote’s outstanding common stock as of June 8, 2026, with an additional option grant for the same percentage if he becomes non-interim CEO. The agreement provides 12 months of salary and health insurance benefits if he is terminated without cause or resigns for specified good reasons, with enhanced payments (salary plus target bonus and accelerated vesting of certain equity awards) if such a termination occurs around a change in control.
biote Corp. interim CEO Robert Charles Peterson received a grant of stock options as part of his compensation. The award covers 206,746 options to purchase Class A common stock at an exercise price of $2.46 per share and expires on June 11, 2036. According to the vesting terms, 25% of the options will vest on June 12, 2027, with the remaining options vesting in 36 substantially equal monthly installments, subject to his continued service. Following this grant, Peterson holds 206,746 stock options directly, and the filing does not report any open-market share purchases or sales.
biote Corp. director Bret Christensen received a grant of stock options, giving him the right to buy 130,000 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.
All 130,000 option shares will vest on the earlier of June 8, 2027 or the day before biote Corp.'s 2027 Annual Meeting of Stockholders, as long as Christensen remains in continuous service through that vesting date.